Ascendis Pharma A/S

NasdaqGS:ASND Stock Report

Market Cap: US$12.7b

Ascendis Pharma Valuation

Is ASND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ASND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$781.27
Fair Value
73.5% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: ASND ($207.03) is trading below our estimate of fair value ($781.27)

Significantly Below Fair Value: ASND is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ASND?

Key metric: As ASND is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ASND. This is calculated by dividing ASND's market cap by their current revenue.
What is ASND's PS Ratio?
PS Ratio22x
Sales€490.75m
Market Cap€10.82b

Price to Sales Ratio vs Peers

How does ASND's PS Ratio compare to its peers?

The above table shows the PS ratio for ASND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average30.5x
BBIO BridgeBio Pharma
44.6x42.24%US$10.8b
RYTM Rhythm Pharmaceuticals
47.3x43.85%US$7.3b
LEGN Legend Biotech
7.5x26.46%US$6.2b
PTGX Protagonist Therapeutics
22.5x22.47%US$4.8b
ASND Ascendis Pharma
22x34.82%US$12.7b

Price-To-Sales vs Peers: ASND is good value based on its Price-To-Sales Ratio (22x) compared to the peer average (30.5x).

Price to Sales Ratio vs Industry

How does ASND's PS Ratio compare vs other companies in the US Biotechs Industry?

153 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.6x2.20%US$160.07b
REGN Regeneron Pharmaceuticals
4.2x6.21%US$59.77b
BIIB Biogen
2.1x-1.20%US$21.06b
INCY Incyte
3.7x1.82%US$17.21b
ASND 22.0xIndustry Avg. 11.3xNo. of Companies153PS020406080100+
153 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ASND is expensive based on its Price-To-Sales Ratio (22x) compared to the US Biotechs industry average (11.1x).

Price to Sales Ratio vs Fair Ratio

What is ASND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ASND PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio22x
Fair PS Ratio16.7x

Price-To-Sales vs Fair Ratio: ASND is expensive based on its Price-To-Sales Ratio (22x) compared to the estimated Fair Price-To-Sales Ratio (16.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ASND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$207.03
US$249.47
+20.50%
8.65%US$298.24US$218.03n/a14
Oct ’26US$204.11
US$248.94
+21.96%
11.33%US$308.66US$203.17n/a15
Sep ’26US$194.27
US$251.76
+29.59%
11.54%US$308.16US$203.31n/a16
Aug ’26US$174.48
US$233.79
+33.99%
13.56%US$302.22US$195.64n/a16
Jul ’26US$172.00
US$231.81
+34.77%
12.44%US$298.40US$194.30n/a16
Jun ’26US$162.84
US$223.60
+37.31%
12.49%US$289.36US$196.24n/a16
May ’26US$167.47
US$210.50
+25.69%
14.07%US$289.36US$167.30n/a16
Apr ’26US$151.43
US$208.83
+37.91%
14.66%US$287.91US$159.87n/a15
Mar ’26US$156.58
US$202.52
+29.34%
16.22%US$286.99US$160.76n/a15
Feb ’26US$130.66
US$193.19
+47.85%
17.90%US$289.84US$125.95n/a15
Jan ’26US$137.67
US$192.74
+40.00%
16.93%US$290.45US$151.32n/a14
Dec ’25US$136.08
US$191.65
+40.84%
16.55%US$288.39US$152.68n/a14
Nov ’25US$125.28
US$195.66
+56.18%
15.45%US$287.71US$160.71n/a14
Oct ’25US$146.60
US$193.99
+32.33%
15.77%US$287.75US$156.24US$204.1113
Sep ’25US$138.45
US$193.99
+40.11%
14.83%US$279.11US$165.90US$194.2712
Aug ’25US$136.53
US$181.72
+33.10%
15.15%US$260.37US$140.23US$174.4812
Jul ’25US$133.98
US$183.29
+36.80%
16.33%US$262.96US$138.32US$172.0013
Jun ’25US$135.10
US$183.44
+35.78%
17.01%US$265.67US$139.74US$162.8413
May ’25US$141.01
US$177.33
+25.76%
19.31%US$259.53US$112.97US$167.4712
Apr ’25US$151.98
US$179.28
+17.96%
19.30%US$259.97US$115.56US$151.4312
Mar ’25US$152.47
US$172.80
+13.34%
14.28%US$226.19US$117.22US$156.5812
Feb ’25US$141.63
US$163.23
+15.25%
13.89%US$204.75US$117.59US$130.6612
Jan ’25US$125.95
US$149.91
+19.02%
13.06%US$203.32US$119.61US$137.6712
Dec ’24US$104.05
US$143.50
+37.91%
16.72%US$200.02US$112.41US$136.0812
Nov ’24US$90.79
US$141.57
+55.93%
16.90%US$192.33US$109.24US$125.2812
Oct ’24US$93.64
US$141.51
+51.13%
17.75%US$191.63US$109.89US$146.6011
US$249.47
Fair Value
17.0% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/16 17:59
End of Day Share Price 2025/10/16 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascendis Pharma A/S is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Michelle GilsonCanaccord Genuity
Alethia YoungCantor Fitzgerald & Co.